- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 413/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Patent holdings for IPC class C07D 413/02
Total number of patents in this class: 203
10-year publication summary
|
13
|
13
|
12
|
8
|
11
|
9
|
5
|
9
|
8
|
11
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2190 |
8 |
| Boehringer Ingelheim International GmbH | 4644 |
7 |
| Centrexion Therapeutics Corporation | 64 |
6 |
| Abbvie Inc. | 1813 |
5 |
| Epizyme, Inc. | 374 |
5 |
| Genentech, Inc. | 4006 |
4 |
| Syngenta Crop Protection AG | 6229 |
4 |
| Bristol-myers Squibb Company | 4833 |
3 |
| Samsung Display Co., Ltd. | 36065 |
3 |
| MEI Pharma, Inc. | 55 |
3 |
| Merck Sharp & Dohme LLC | 3735 |
3 |
| F. Hoffmann-La Roche AG | 7931 |
2 |
| Merck Patent GmbH | 5758 |
2 |
| Bayer HealthCare LLC | 1332 |
2 |
| Takeda Pharmaceutical Company Limited | 2719 |
2 |
| Alexion Pharmaceuticals, Inc. | 640 |
2 |
| Alkahest, Inc. | 98 |
2 |
| Astex Therapeutics Limited | 233 |
2 |
| Cancer Research Technology Limited | 523 |
2 |
| Celgene Corporation | 1410 |
2 |
| Other owners | 134 |